相关实验视频
Updated: May 13, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
压力颗粒核心蛋白质G3BP1通过减弱肝细胞脂质沉积来改善与代谢功能障碍相关的脂肪肝疾病
Xingjing Liu1, Huimei Yu2, Tongtong Hu3
1Department of Endocrinology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, China.
压力颗粒可以防止与代谢功能障碍相关的脂肪肝疾病 (MAFLD) 的进展. 击败G3BP1,一个关键的压力颗粒蛋白,通过可能增加APOC3核入口,加剧了MAFLD.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 细胞生物学 细胞生物学
- 分子机制的分子机制
背景情况:
- 异常的脂质积累驱动了代谢功能障碍相关的脂肪肝疾病 (MAFLD) 的进展.
- 细胞应激反应与MAFLD病变发生有关.
- 压力颗粒 (SG) 在MAFLD中的作用仍然未被探索.
研究的目的:
- 研究压力颗粒 (SG) 在MAFLD中的作用和分子机制.
- 为了确定SG在MAFLD中是否起着保护性或有害的作用.
主要方法:
- 在小鼠模型和 HepG2 细胞中,G3BP1 (核心 SG 蛋白质) 的基因敲除.
- 使用高脂肪饮食 (体内) 或棕酸 (PA) (体内) 诱导MAFLD.
- 分析包括代谢表型化,西部涂抹,qPCR,免疫光学,组织学和RNA测序 (RNA-seq).
主要成果:
- 在MAFLD模型中,G3BP1和TIA1的表达和局部化增加.
- 缺乏G3BP1会加剧肝脏脂质沉积和胰岛素抵抗.
- RNA-seq揭示G3BP1通过抑制APOC3核进入来抑制MAFLD的进展.
结论:
- 压力颗粒 (SGs) 在MAFLD中起着保护作用.
- 缺乏G3BP1会通过可能涉及APOC3核转移的机制加剧MAFLD.
- 这些发现为MAFLD提供了新的治疗点.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:35A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
Published on: May 18, 2021
相关概念视频
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Dipeptidyl Peptidase 4 Inhibitors
GPCRs Regulate Adenylyl Cylase Activity